Bionor Immuno
Bionor Immuno AS is a multidisciplinary biomedical drug development company with a well-established platform technology for the development of therapeutic ...
http://www.bionorimmuno.com/...
|
Bionor Immuno Release: Researchers Find That Vacc-4x Therapeutic ...
21 Oct 2009 ... Bionor Immuno is in the process of initiating a new Vacc-4x program that seeks to help people with HIV who do not respond adequately to ...
http://www.biospace.com/news_story.aspx?NewsEntityId=159998...
|
Bionor Immuno / contact
Bionor Immuno AS is an innovative biotech company developing vaccines stimulating cell-mediated immunity. The company has developed a unique peptide
design ...
http://www.bionorimmuno.com/contact.html...
|
Bionor Immuno Welcomes Renowned Virologist Robert Redfield, MD...
Bionor Immuno announced today at the AIDS Vaccine 2009 conference in Paris, France, that Robert Redfield, MD, Associate Director and Co-Founder of the ...
http://www.biospace.com/news_story.aspx?NewsEntityId=159592...
|
Bionor Immuno / news
Researchers Hope Bionor Immuno's Immune Modulating Investigational Treatment Gives HIV Patients a Safe Break from Anti Retroviral Therapy-- ...
http://www.bionorimmuno.com/news2008_award.html...
|
Novel peptide-based HIV-1 immunotherapy.
Bionor Immuno AS, Strømdaljordet 4, PO Box 1823 Gulset, NO-3703 Skien, Norway. Maja.sommerfelt@bionorimmuno.com. Therapeutic immunisation of human ...
http://www.ncbi.nlm.nih.gov/pubmed/15006729...
|
Bionor Immuno / news
28 Jan 2009 ... "Bionor Immuno and Bachem sign agreement on supply of active ingredients and finished dosage forms for Bionor Immuno's vaccine development ...
http://www.bionorimmuno.com/news2009_Bachem.html...
|
Circular CCR5 peptide conjugates and uses thereof (WO2008074895).
Bionor Immuno AS, Klostergata 33, NO-3702 Skien, Norway. ms@bionorimmuno.com. BACKGROUND: Several new strategies targeting HIV infection aim to inhibit ...
http://www.ncbi.nlm.nih.gov/pubmed/19456281...
|
Bionor Immuno / news
Mexico City, Mexico – August 4, (PR Newswire) —Bionor Immuno today announced that it has advanced its efforts to develop the first HIV therapeutic ...
http://www.bionorimmuno.com/news2008_phaseIIB.html...
|
Multiple antigen concentrations in delayed-type hypersensitivity ...
Bionor Immuno AS, P.O. Box. 1823, NO-3703 Skien, Norway. jorgen.nyhus@ bionorimmuno.com. Delayed-type hypersensitivity (DTH) testing represents a
simple in ...
http://www.ncbi.nlm.nih.gov/pubmed/16289707...
|
